Table 2: Differences between the nHTA programs for medical technologies and pharmaceutical products.
1The ‘Center for nHTA’ at HIRA was responsible for the nHTA program since its introduction in June 2007, but NECA took over responsibility in June 2010.
2BIA : Budget Impact Analysis; CEA : Cost-Effectiveness Analysis; CMA : Cost-Minimization Analysis; CUA : Cost-Utility Analysis; ICER : Incremental Cost-Effectiveness Ratio
| Medical technologies | Pharmaceuticals products |
| Legislation | Medical Service Act | National Health Insurance Act |
| Organization in charge | NECA (supervised by MOHW)1 | HIRA (supervised by MOHW) |
| Assessment aspect | Safety and efficacy (effectiveness) | Economic evaluation |
| Assessment tool2 | Systematic review | CMA; ICER value, determined using CEA or CUA; BIA |